Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07269392

Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer

Impact of dual trigger using recombinant human chorionic gonadotropin (HCG) and gonadotropin-releasing hormone (GnRH) agonist on thawed modified natural cycle outcomes: an open-label multi-center randomized controlled trial.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

In Vitro Fertilization (IVF) Embryo Transfer

Age range

25 year–44 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 24<= Age < 45 patient undergo mNC-FET

Exclusion criteria

  • Congenital or acquired uterine abnormalities (uterine malformation, submucosal myoma, intrauterine adhesion or endometrial polyp >1cm)

Treatment and study plan

GnRH agonist

Drug

GnRH agonist add to hcg for trigger

Primary outcomes

  1. Implantation

    Time frame: 14 days after embryo transfer

    Implantation is defined as a positive serum β-hCG (>20 mIU/mL) measured 14 days after embryo transfer.

Secondary outcomes

  1. Clinical pregnancy

    Time frame: one week after confirm pregnancy

    Clinical pregnancy is defined as visualization of a gestational sac on transvaginal ultrasonography one week after pregnancy has been confirmed.

  2. Ongoing pregnancy rate

    Time frame: 5 weeks after confirmed pregnancy

    An ongoing pregnancy is defined as a viable intrauterine pregnancy with fetal cardiac activity at ≥9 weeks' gestational age.

  3. Miscarriage rate

    Time frame: before delivery

  4. Gestational age (weeks) at delivery

    Time frame: delivery

    Gestational age (weeks) at delivery

  5. Live birth rate

    Time frame: delivery

  6. Birth weight

    Time frame: delivery

    Birth weight of the bewborn (kg)

  7. Presence of significant congenital or medical conditions of the newborn

    Time frame: delivery

    Presence of significant congenital or medical conditions of the newborn

Study contacts

Contact information is provided by the study sponsor or research team.

william lee

CONTACT

[email protected]

+886972652396

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

Impact of Dual Trigger Using Recombinant Human Chorionic Gonadotropin (HCG) and Gonadotropin-releasing Hormone (GnRH) Agonist on Thawed Modified Natural Cycle Outcomes: an Open-label Multi-center Randomized Controlled Trial.

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Dec 8, 2025
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.